Telisotuzumab vedotin
Product Specifications
UNSPSC Description
Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used in cancer research[1].
Target Antigen
Antibody-Drug Conjugates (ADCs); c-Met/HGFR
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related;Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/telisotuzumab-vedotin.html
Solubility
DMSO : ≥ 100 mg/mL
Smiles
[Telisotuzumab vedotin]
Molecular Weight
145000 (average)
References & Citations
[1]Strickler JH, et al. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 Nov 20;36(33):3298-3306.
Shipping Conditions
Dry Ice
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-141601/Telisotuzumab-vedotin-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-141601/Telisotuzumab-vedotin-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
1714088-51-3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
